The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation

AIM OF THE STUDY: To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in the management of DLBCL. MATERIAL AND METHODS: Patients with primary refractory or high-risk DLBCL (n = 18), ineligible for autologous stem-cell transplantation, were inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurczak, Wojciech, Kisiel, Elżbieta, Sawczuk-Chabin, Joanna, Centkowski, Piotr, Knopińska-Posłuszny, Wanda, Khan, Omeir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2015
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507887/
https://www.ncbi.nlm.nih.gov/pubmed/26199570
http://dx.doi.org/10.5114/wo.2015.50012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507887/
https://www.ncbi.nlm.nih.gov/pubmed/26199570
http://dx.doi.org/10.5114/wo.2015.50012

Ejemplares similares